Skip to content

A clinical study of Fulminating moxibustion to alleviate enteral nutritional intolerance in early acute pancreatitis

A clinical study of Lei Huo moxibustion to alleviate enteral nutritional intolerance in early acute pancreatitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080974
Enrollment
Unknown
Registered
2024-02-19
Start date
2023-07-11
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

Control group:Conventional treatment care: (1) Fluid therapy(2)Analgesic treatment, nursing(3)Nutritional support and care
Experimental group:Based on the control group, Lei Huo moxibustion QD,

Sponsors

Jiangsu Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1). Those who meet the diagnostic criteria for acute pancreatitis and the differentiation criteria for spleen and stomach weakness in traditional Chinese medicine. (2). Be between 18 and 70 years old, and have no gender limit. (3). Acute onset, admission within 72 hours after the appearance of typical abdominal symptoms. (4). No nutritional support before admission; (5). Patients with nasal jejunal nutrition and enteral nutrition (6). Symptoms of enteral nutritional intolerance (7). Intestinal sounds 10 times/min (8). Enteral nutrition tolerance score [38]: =3 points (9). Informed consent, voluntary testing. The process of obtaining informed consent should comply with GCP regulations.

Exclusion criteria

Exclusion criteria: (1). Pancreatitis of pregnancy; (2). Autoimmune pancreatitis (3). Patients with gastrointestinal tumors and surgery (4). Combined with multiple organ failure, need ventilator treatment (5). Pregnant and lactating women. (6). Those who cannot give full informed consent due to intellectual or behavioral disabilities. (7). Suspected or confirmed history of alcohol and drug abuse. (8). According to the judgment of the investigator, other lesions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in the working environment, are likely to cause loss to follow-up. (9). Allergic constitution, such as a history of allergy to two or more drugs or foods; or known to be allergic to the ingredients of this drug. (10). Fever patients. (11). Patients who are participating in clinical trials of other drugs.

Design outcomes

Primary

MeasureTime frame
Harvest the target energy (25kcal/(kg·d) to reach the time;

Secondary

MeasureTime frame
Actual daily nutrient intake;Abdominal circumference;Severity of the disease;weight;BMI index;Water content, muscle mass;Enteral nutritional intolerance score;Fluctuations in bowel sounds; serum interleukin-6; hypersensitivity C-reactive protein;Serum albumin;Serum pre-albumin ;haemoglobin;

Countries

China

Contacts

Public ContactLiu Chengcheng Wu Li

Jiangsu Provincial Hospital of Traditional Chinese Medicine

491396298@qq.com+86 138 1381 0450

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026